SPOTLIGHT -
Dr. Roué on the Rationale for Evaluating TG-1701 in Ibrutinib-Resistant MCL Models
Gaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.
Read More
Dr. Roué on the Next Steps With TG-1701 in MCL
Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the next steps with the investigational BTK inhibitor TG-1701 in mantle cell lymphoma.
Dr. Roué on Interest With TG-1701 in Ibrutinib-Resistant MCL Models
Gaël Roué, PhD, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma.
Dr. Roué on the Synergistic Activity With TG-1701, Ublituximab, and Umbralisib in MCL
Gaël Roué, PhD, discusses the synergistic activity with TG-1701, ublituximab, and umbralisib in ibrutinib-resistant mantle cell lymphoma models.
Immunotherapy Must Become More Precise and Personalized
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
